Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Liabilities and Shareholders Equity (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Liabilities and Shareholders Equity data on record, last reported at $80.5 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 36.83% year-over-year to $80.5 million; the TTM value through Sep 2025 reached $298.3 million, up 42.71%, while the annual FY2024 figure was $68.9 million, 51.27% up from the prior year.
  • Liabilities and Shareholders Equity reached $80.5 million in Q3 2025 per CRVS's latest filing, down from $89.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $101.3 million in Q1 2022 and bottomed at $40.1 million in Q1 2024.
  • Average Liabilities and Shareholders Equity over 4 years is $67.9 million, with a median of $64.6 million recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: plummeted 42.54% in 2023, then soared 51.27% in 2024.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $68.2 million in 2022, then tumbled by 33.25% to $45.6 million in 2023, then surged by 51.27% to $68.9 million in 2024, then grew by 16.79% to $80.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $80.5 million in Q3 2025, $89.5 million in Q2 2025, and $59.4 million in Q1 2025.